Which one is the best option for you?
WASHINGTON — The United States has an emergency fund for people suffering from conjunctivist strokes, but a new study suggests it’s not as effective as it could be.
A new study from researchers at Columbia University suggests the fund is no better than a placebo.
Conjunctival strokes are often treatable with medications but they’re a devastatingly slow process.
A study published in the journal Neurology found that a typical stroke victim has a stroke recovery rate of less than 10 percent.
The researchers looked at stroke victims who had had at least one stroke and then treated them with either a placebo or a stroke-specific treatment.
“The most important finding is that a stroke is not a cure,” said lead author and Columbia neurologist Dr. Peter Mather.
“It can be an extremely helpful tool, and we don’t know what it will be for other patients.”
In other words, you can’t give a stroke patient a placebo and expect them to recover.
Mather said the stroke treatment had no effect on the patients’ risk of developing dementia, but it was enough to reduce their stroke recovery rates by at least 30 percent.
He said the new study was an interesting test for the stroke-treatment concept, and it suggested the concept was valuable for other stroke victims.
“There are many possible treatments that have been studied for stroke patients and they haven’t had the greatest success,” he said.
“But this study was the first to look at stroke patients who have had one stroke, and that’s what we really wanted to test.”
The study is the first one to look for differences in stroke recovery among stroke patients treated with stroke-Specific and stroke-Treatment Treatments, Mather said.
He and his team also studied patients with mild to moderate stroke and found no difference in recovery rates.
Dr. Steven Zang, a stroke specialist at the University of Utah, said the study is important because it shows the value of stroke-based treatments for stroke victims, but they need to be carefully selected.
“I think it’s important that we keep a very open mind about stroke patients,” he told ABC News.
“I think that the idea that it is beneficial for stroke survivors to get these treatments and then be cured of stroke is probably misguided.”
For many stroke victims the effects of a stroke can last for years.
Many don’t recover.
And the stroke recovery isn’t always as quick as the effects on people with dementia.
“We don’t really know what causes strokes,” Mather added.
“This is something that could help us understand what causes stroke recovery.”
The findings are preliminary, and Mather and his colleagues said they want to see more research to confirm their findings.
They hope the findings could help stroke victims get the stroke treatments they need and reduce their risk of dementia and other serious illnesses.
Mullins Healthcare and the Stroke Foundation will be releasing the results of the study next month.
Mellow, M.C., and Zang were not involved in the study.